Last reviewed · How we verify
MIDCAB
MIDCAB is a minimally invasive surgical technique for coronary artery bypass grafting that uses a small thoracotomy incision instead of full sternotomy to access and graft coronary arteries.
MIDCAB is a minimally invasive surgical technique for coronary artery bypass grafting that uses a small thoracotomy incision instead of full sternotomy to access and graft coronary arteries. Used for Coronary artery disease amenable to bypass grafting via minimally invasive approach, Left anterior descending (LAD) coronary artery stenosis.
At a glance
| Generic name | MIDCAB |
|---|---|
| Also known as | Bupivacaine and dexamethasone |
| Sponsor | Hospital for Special Surgery, New York |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
MIDCAB (Minimally Invasive Direct Coronary Artery Bypass) is a surgical procedure rather than a pharmacological drug. It involves grafting a vessel (typically the internal mammary artery) to bypass a blocked coronary artery through a small left anterior thoracotomy incision, avoiding the need for full median sternotomy and cardiopulmonary bypass in selected cases. This approach reduces surgical trauma, recovery time, and postoperative morbidity compared to conventional open-heart bypass surgery.
Approved indications
- Coronary artery disease amenable to bypass grafting via minimally invasive approach
- Left anterior descending (LAD) coronary artery stenosis
Common side effects
- Bleeding/transfusion requirement
- Arrhythmia
- Myocardial infarction
- Stroke
- Graft failure
Key clinical trials
- Effect of PECS II, Parasternal and Serratus Plane Blocks on Postoperative Pain in MIDCAB Surgery (NA)
- MIDCAB (Mid-Calf Block) for Foot Surgery (PHASE4)
- Robotically-assisted Minimally-invasive Direct Coronary Artery Bypass With Stenting, Randomized Against Coronary Artery Bypass Graft Surgery (NA)
- Hybrid Revascularization Versus Coronary Artery Bypass Grafting (NA)
- FUNctional eFficacy of Hybrid coronAry REvascularization (NA)
- Effects of Fluid Therapy on Microcirculatory Reactivity (NA)
- Efficacy and Safety of One-Stage Hybrid Coronary Revascularization (NA)
- Prospective Cohort Study on Minimal Invasive Coronary Surgery
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MIDCAB CI brief — competitive landscape report
- MIDCAB updates RSS · CI watch RSS
- Hospital for Special Surgery, New York portfolio CI